Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The real-world cure rates offered by Sovaldi (sofosbuvir)-based hep C virus regimens have not been as good as those seen in clinical trials
The FDA has approved BMS’s Daklinza (daclatasvir) to be used with Gilead Sciences’ Sovaldi (sofosbuvir) to treat genotype 3 of hepatitis C.
The American Association for the Study of Liver Diseases has updated the treatment guidelines for hepatitis C.
Harvoni and the combination of Sovaldi and daclatasvir were the least likely to cause a severe reaction with the HIV regimens of a cohort of H...
Nine people taking Harvoni or Sovaldi and the heart medication Cordarone (amiodarone) have suffered from low heartbeats; one died of a heart a...
Researchers presented results from various studies on hepatitis C treatment and care at a medical conference in Seattle.
People who coinfected with HIV and hepatitis C looking to take the HCV drug Olysio may need to change HIV medications to avoid drug-drug...
The pharmacy benefit manager Express Scripts has will only reimburse for AbbVie’s hepatitis C regimen for people with genotype 1 of the virus.
The FDA has granted approval of Olysio (simeprevir) and Sovaldi (sofosbuvir) to be used in combination to treat genotype 1 of hepatitis C.
The first once-daily fixed-dose combination therapy to treat hep C has hit the scene, with neither interferon nor ribavirin in tow.
About 25 percent of people living with HIV in the United States are co-infected with HCV.
Low-dose daclatasvir and Olysio (simeprevir) cured a relatively high proportion of people with genotype 1b of hepatitis C, but just two thirds...
As hepatitis C treatment undergoes a revolution akin to the introduction of HIV antiretrovirals, the doors are swinging wide open for people c...
With the FDA approval of Sovaldi (sofosbuvir) and Olysio (simeprevir), many people with hepatitis C, including those coinfected with HIV...
The FDA has approved Sovaldi (sofosbuvir), a once-daily oral nucleotide analog polymerase inhibitor to treat people with hepatitis C.
The looming threat of a government shutdown on October 1 may spell potential delays in Food and Drug Administration approvals of new drugs.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.